Hill-Rom Cites Diagnostics, Monitoring Synergies In $2 Bil. Welch-Allyn Buy
This article was originally published in The Gray Sheet
Executive Summary
The stock and cash deal announced June 17 will create a company with $2.6 billion in combined annual sales. The merger will join Hill-Rom's leading position in hospitals and operating room offerings with Welch Allyn's leading position in point-of-care diagnostics and testing, the companies say.